Takeda’s Mimrylo (rusfertide) won U.S. FDA clearance for adults with polycythemia vera, a rare blood cancer marked by excessive red blood cell production. The therapy is a weekly injectable hepcidin mimetic developed by Protagonist Therapeutics and marketed by Takeda in the U.S. The approval builds on phase 3 evidence that positioned rusfertide as a hepcidin-pathway approach designed to address the underlying imbalance in PV. For companies with hematology platforms, the labeling expands the category of hepcidin-modulating agents into a commercially defined niche with clear regulatory precedent, while also reinforcing Takeda’s strategy of expanding into precision hematology. Clinicians and payers will now focus on uptake, administration logistics, and comparative positioning versus existing PV management strategies.